- Report
- April 2025
- 175 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- December 2025
- 200 Pages
Global
From €2619EUR$2,990USD£2,273GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2026
- 485 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 483 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 377 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- July 2025
- 175 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1095EUR$1,250USD£950GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €2190EUR$2,500USD£1,900GBP
- Report
- January 2026
- 186 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2443EUR$2,789USD£2,120GBP
- Report
- March 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- November 2025
- 196 Pages
Global
From €4335EUR$4,950USD£3,763GBP
- Report
- June 2025
- 200 Pages
United States
From €2181EUR$2,490USD£1,893GBP
- Report
- August 2022
- 115 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- August 2024
- 233 Pages
Global
From €6963EUR$7,950USD£6,043GBP
- Report
- January 2024
- 395 Pages
Global
From €6569EUR$7,500USD£5,701GBP
- Report
- June 2024
- 185 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- May 2024
- 132 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- May 2024
- 138 Pages
Global
From €3502EUR$3,999USD£3,040GBP

Epidiolex is a pharmaceutical drug used to treat certain types of epilepsy. It is the first FDA-approved drug derived from cannabidiol (CBD), a component of the cannabis plant. Epidiolex is used to treat two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is classified as a central nervous system (CNS) drug, which are drugs that act on the brain and spinal cord to treat neurological disorders.
Epidiolex is manufactured by GW Pharmaceuticals, a British biopharmaceutical company. It is distributed in the United States by Greenwich Biosciences, a subsidiary of GW Pharmaceuticals. Other companies in the CNS drug market include AbbVie, Allergan, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more